ctDNA Identifies Acquired Resistance Mechanisms to Savolitinib in MET+ Gastric Cancer
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.
Enhertu granted Orphan Drug Designation in the US for gastric cancer
AstraZeneca and Daiichi Sankyo won breakthrough designation and orphan drug designation from the FDA for Enhertu in treating HER2-positive gastric cancer, which... Read More
ASCO: In stomach cancer, AstraZeneca and Daiichi’s Enhertu goes where Roche’s Kadcyla couldn’t
In a pivotal study, patients taking Enhertu from AstraZeneca and Daiichi Sankyo saw their tumors shrink and were still alive after a... Read More
Low-Dose Aspirin Might Lower Odds for Digestive Cancers
Low-dose aspirin may reduce the risk of digestive tract cancers, including gastric cancer, according to European researchers who analyzed 113 studies and... Read More
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Five Prime Therapeutics’ investigational drug bemarituzumab showed promising efficacy in the late-line treatment of gastroesophageal junction adenocarcinoma.
ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
ALX Oncology won fast-track designation from the FDA for its drug ALX148 in the second-line treatment of patients with HER2-positive gastric cancer.
Immunotherapy with Anti-PD-1 Effective for Patients with Solid Tumors
A review of 13 clinical trials published in JAMA Oncology found that patients with solid tumors, including stomach tumors, had better survival... Read More
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
At ASCO GI, Leap Therapeutics announced that in a trial of DKN-01 in patients with advanced gastric cancer, elevated expression of DKK1... Read More
Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Blueprint Medicines won FDA approval for Ayvakit (avapritinib), the first treatment for gastrointestinal stromal tumors (GISTs) that targets platelet-derived growth factor alpha... Read More
Preventing Gastric Cancer Development by Inhibiting the Virulence of H. pylori Infection
New clinical trials will examine the use of the drug DFMO for preventing gastric cancer in people with the H. Pylori infection
